TGF-β1 specific antibodies and methods and uses thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 13, 2016
Issued Date -
N/A
app pub date -
Mar 6, 2013
filing date -
Mar 8, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-β1) are provided, particularly recognizing human and mouse TGF-β1 and not recognizing or binding TGF-β2 or TGF-β3. Particular antibodies are provided which specifically recognize and neutralize TGF-β1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.
First Claim
Other Claims data not available
Family
International Classification(s)
- 2013 Application Filing Year
- A61K Class
- 12711 Applications Filed
- 11051 Patents Issued To-Date
- 86.95 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 1 Citation Count
- A61K Class
- 38.16 % this patent is cited more than
- 9 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Jun 13, 2028 |
